Iterum Therapeutics Plc (ITRM) Tops Q4 EPS by 63c

Iterum Therapeutics Plc (NASDAQ: ITRM) reported Q4 EPS of ($0.52), $0.63 better than the analyst estimate of ($1.15).

For earnings history and earnings-related data on Iterum Therapeutics Plc (ITRM) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Nucor projects Q3 2026 earnings above prior year, below estimates
• Intuit holds investor day, reaffirms fiscal 2027 guidance